Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study
- PMID: 26168366
- PMCID: PMC4925099
- DOI: 10.7326/M14-0960
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study
Abstract
Background: Ulcerative colitis (UC) can be treated with surgery or medications. Patients often must choose between long-term immunosuppressant therapy or total colectomy. Whether one of these treatment approaches has a mortality benefit is uncertain.
Objective: To determine whether patients with advanced UC treated with elective colectomy have improved survival compared with those treated with medical therapy.
Design: Retrospective matched cohort study.
Setting: Data from all 50 states for Medicaid beneficiaries (2000 to 2005), Medicare beneficiaries (2006 to 2011), and dual-eligible persons (2000 to 2011).
Patients: 830 patients with UC pursuing elective colectomy and 7541 matched patients with UC pursuing medical therapy.
Measurements: The primary outcome was time to death. Cox proportional hazards models were used to compare the survival of patients with advanced UC treated with elective colectomy or medical therapy. The models controlled for significant comorbid conditions through matched and adjusted analysis.
Results: The mortality rates associated with elective surgery and medical therapy were 34 and 54 deaths per 1000 person-years, respectively. Elective colectomy was associated with improved survival compared with long-term medical therapy (adjusted hazard ratio [HR], 0.67 [95% CI, 0.52 to 0.87]), although this result did not remain statistically significant in all sensitivity analyses. Post hoc analysis by age group showed improved survival with surgery in patients aged 50 years or older with advanced UC (HR, 0.60 [CI, 0.45 to 0.79]; P = 0.032 for age-by-treatment interaction).
Limitations: Retrospective nonrandomized analysis is subject to residual confounding. The source cohort was derived from different databases throughout the study. Sensitivity and secondary analyses had reduced statistical power.
Conclusion: Elective colectomy seemed to be associated with improved survival relative to medical therapy among patients aged 50 years or older with advanced UC.
Primary funding source: National Institutes of Health and Agency for Healthcare Research and Quality.
Figures
Comment in
-
Mortality associated with medical therapy in ulcerative colitis.Ann Intern Med. 2015 Aug 18;163(4):I-28. doi: 10.7326/P15-9026. Ann Intern Med. 2015. PMID: 26168403 No abstract available.
-
Elective surgery for ulcerative colitis is associated with lower mortality than drug treatment in older patients.BMJ. 2015 Jul 13;351:h3806. doi: 10.1136/bmj.h3806. BMJ. 2015. PMID: 26175044 No abstract available.
-
Elective colectomy for severe ulcerative colitis may reduce mortality more than medical therapy.Evid Based Med. 2016 Feb;21(1):29. doi: 10.1136/ebmed-2015-110311. Epub 2015 Dec 7. Evid Based Med. 2016. PMID: 26642847 No abstract available.
Similar articles
-
Immunosuppressant medications and mortality in inflammatory bowel disease.Am J Gastroenterol. 2008 Jun;103(6):1428-35; quiz 1436. doi: 10.1111/j.1572-0241.2008.01836.x. Epub 2008 May 20. Am J Gastroenterol. 2008. PMID: 18494836
-
Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common.Dig Dis Sci. 2018 Mar;63(3):713-722. doi: 10.1007/s10620-018-4922-x. Epub 2018 Jan 20. Dig Dis Sci. 2018. PMID: 29353444
-
Colectomy is a risk factor for venous thromboembolism in ulcerative colitis.World J Gastroenterol. 2015 Jan 28;21(4):1251-60. doi: 10.3748/wjg.v21.i4.1251. World J Gastroenterol. 2015. PMID: 25632199 Free PMC article.
-
Management of Ulcerative Colitis in the Elderly.Drugs Aging. 2019 Jan;36(1):13-27. doi: 10.1007/s40266-018-0611-x. Drugs Aging. 2019. PMID: 30515708 Review.
-
A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease.Inflamm Bowel Dis. 2013 Aug;19(9):2001-10. doi: 10.1097/MIB.0b013e318281f3bb. Inflamm Bowel Dis. 2013. PMID: 23624887 Review.
Cited by
-
Micronutrient deficiencies in older patients with inflammatory bowel disease are not associated with worse adverse clinical outcome rates.Ann Gastroenterol. 2024 Sep-Oct;37(5):536-542. doi: 10.20524/aog.2024.0900. Epub 2024 Jul 12. Ann Gastroenterol. 2024. PMID: 39238798 Free PMC article.
-
Frailty: An Underappreciated Risk Factor for IBD Complications.Curr Gastroenterol Rep. 2024 Dec;26(12):315-322. doi: 10.1007/s11894-024-00945-5. Epub 2024 Sep 5. Curr Gastroenterol Rep. 2024. PMID: 39235680 Review.
-
Natural course of ulcerative colitis in China: Differences from the West?United European Gastroenterol J. 2024 Nov;12(9):1167-1178. doi: 10.1002/ueg2.12634. Epub 2024 Jul 19. United European Gastroenterol J. 2024. PMID: 39031457 Free PMC article.
-
Management Considerations for the Older Adult With Inflammatory Bowel Disease.Gastroenterol Hepatol (N Y). 2023 Oct;19(10):592-599. Gastroenterol Hepatol (N Y). 2023. PMID: 38404957 Free PMC article.
-
Long-Term Surgical Outcomes and Pathological Analysis of Proctectomy Specimens after Subtotal Colectomy for Ulcerative Colitis: A Retrospective Cohort Study from a Tertiary Centre.J Clin Med. 2023 Sep 2;12(17):5729. doi: 10.3390/jcm12175729. J Clin Med. 2023. PMID: 37685796 Free PMC article.
References
-
- Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn’s disease. Gastroenterol Clin North Am. 2004;33(2):303. - PubMed
-
- Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621–30. - PubMed
-
- Toruner M, Loftus EV, Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–36. - PubMed
-
- Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103(6):1428. - PubMed
-
- Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical